MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12015-011-9327-6

Медицинская библиотека · Stem cell reviews and reports · 2012

FGFR2 mutation confers a less drastic gain of function in mesenchymal stem cells than in fibroblasts.

Yeh Erika, Atique Rodrigo, Ishiy Felipe A A, Fanganiello Roberto Dalto, Alonso Nivaldo, Matushita Hamilton, da Rocha Katia Maria, Passos-Bueno Maria Rita

СтатьяПеревод в очереди

Аннотация

Gain-of-function mutations in FGFR2 cause Apert syndrome (AS), a disease characterized by craniosynostosis and limb bone defects both due to abnormalities in bone differentiation and remodeling. Although the periosteum is an important cell source for bone remodeling, its role in craniosynostosis remains poorly characterized. We hypothesized that periosteal mesenchymal stem cells (MSCs) and fibroblasts from AS patients have abnormal cell phenotypes that contribute to the recurrent fusion of the coronal sutures. MSCs and fibroblasts were obtained from the periostea of 3 AS patients (S252W) and 3 control individuals (WT). We evaluated the proliferation, migration, and osteogenic differentiation of these cells. Interestingly, S252W mutation had opposite effects on different cell types: S252W MSCs proliferated less than WT MSCs, while S252W fibroblasts proliferated more than WT fibroblasts. Under restrictive media conditions, only S252W fibroblasts showed enhanced migration. The presence of S252W mutation increased in vitro and in vivo osteogenic differentiation in both studied cell types, though the difference compared to WT cells was more pronounced in S252W fibroblasts. This osteogenic differentiation was reversed through inhibition of JNK. We demonstrated that S252W fibroblasts can induce osteogenic differentiation in periosteal MSCs but not in MSCs from another tissue. MSCs and fibroblasts responded differently to the pathogenic effects of the FGFR2(S252W) mutation. We propose that cells from the periosteum have a more important role in the premature fusion of cranial sutures than previously thought and that molecules in JNK pathway are strong candidates for the treatment of AS patients.

Для цитирования: Yeh Erika, Atique Rodrigo, Ishiy Felipe A A, Fanganiello Roberto Dalto, Alonso Nivaldo, Matushita Hamilton, da Rocha Katia Maria, Passos-Bueno Maria Rita. FGFR2 mutation confers a less drastic gain of function in mesenchymal stem cells than in fibroblasts.. Stem cell reviews and reports. 2012. DOI: 10.1007/s12015-011-9327-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.